Hadasit Bio-Holdings Ltd (HSITF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -29.18 Million ILS | 6.48% |
| 2022 | -31.21 Million ILS | -210.04% |
| 2021 | 28.36 Million ILS | -9.15% |
| 2020 | 31.21 Million ILS | 240.03% |
| 2019 | -22.29 Million ILS | -6955.38% |
| 2018 | -316 Thousand ILS | -102.4% |
| 2017 | 13.17 Million ILS | 906.24% |
| 2016 | -1.63 Million ILS | 90.18% |
| 2015 | -16.64 Million ILS | -193.36% |
| 2014 | -5.67 Million ILS | 62.65% |
| 2013 | -15.19 Million ILS | -39.86% |
| 2012 | -10.86 Million ILS | 50.73% |
| 2011 | -22.04 Million ILS | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -2.51 Million ILS | 61.38% |
| 2023 Q4 | -1.38 Million USD | 44.92% |
| 2023 FY | -29.18 Million ILS | 6.48% |
| 2023 Q1 | -12.08 Million ILS | -727.14% |
| 2023 Q2 | -6.5 Million USD | 46.16% |
| 2022 Q2 | -13.03 Million USD | 0.0% |
| 2022 Q1 | -13.03 Million ILS | -784.28% |
| 2022 FY | -31.21 Million ILS | -210.04% |
| 2022 Q4 | -1.46 Million USD | 43.17% |
| 2022 Q3 | -2.57 Million ILS | 80.28% |
| 2021 FY | 28.36 Million ILS | -9.15% |
| 2021 Q4 | 1.9 Million ILS | 0.0% |
| 2021 Q3 | 1.9 Million ILS | -84.48% |
| 2021 Q1 | 12.27 Million ILS | 185.18% |
| 2021 Q2 | 12.27 Million ILS | 0.0% |
| 2020 Q3 | 4.3 Million ILS | -61.9% |
| 2020 FY | 31.21 Million ILS | 240.03% |
| 2020 Q2 | 11.29 Million ILS | 0.0% |
| 2020 Q1 | 11.29 Million ILS | 295.67% |
| 2020 Q4 | 4.3 Million ILS | 0.0% |
| 2019 Q3 | -5.77 Million ILS | -7.47% |
| 2019 Q1 | -5.37 Million ILS | 0.0% |
| 2019 Q2 | -5.37 Million ILS | 0.0% |
| 2019 FY | -22.29 Million ILS | -6955.38% |
| 2019 Q4 | -5.77 Million ILS | 0.0% |
| 2018 Q1 | 4.97 Million ILS | -76.78% |
| 2018 Q2 | 4.97 Million ILS | 0.0% |
| 2018 FY | -316 Thousand ILS | -102.4% |
| 2017 Q2 | 5.77 Million ILS | 0.0% |
| 2017 FY | 13.17 Million ILS | 906.24% |
| 2017 Q4 | 21.43 Million ILS | 2531.61% |
| 2017 Q1 | 5.77 Million ILS | 785.35% |
| 2017 Q3 | 814.5 Thousand ILS | -85.89% |
| 2016 Q1 | -1.65 Million ILS | 60.0% |
| 2016 Q4 | 652 Thousand ILS | 45.21% |
| 2016 Q3 | 449 Thousand ILS | 141.5% |
| 2016 Q2 | -1.08 Million ILS | 34.54% |
| 2016 FY | -1.63 Million ILS | 90.18% |
| 2015 Q1 | -8.9 Million ILS | -100.45% |
| 2015 Q4 | -4.13 Million ILS | -95.55% |
| 2015 FY | -16.64 Million ILS | -193.36% |
| 2015 Q3 | -2.11 Million ILS | 8.84% |
| 2015 Q2 | -2.31 Million ILS | 73.96% |
| 2014 Q3 | -833 Thousand ILS | -147.68% |
| 2014 Q2 | 1.74 Million ILS | 181.33% |
| 2014 Q4 | -4.44 Million ILS | -433.01% |
| 2014 FY | -5.67 Million ILS | 62.65% |
| 2014 Q1 | -2.14 Million ILS | 68.66% |
| 2013 Q3 | -3.78 Million ILS | 4.4% |
| 2013 FY | -15.19 Million ILS | -39.86% |
| 2013 Q1 | -593 Thousand ILS | 87.69% |
| 2013 Q2 | -3.95 Million ILS | -567.62% |
| 2013 Q4 | -6.85 Million ILS | -81.06% |
| 2012 Q1 | -4.04 Million ILS | 0.0% |
| 2012 FY | -10.86 Million ILS | 50.73% |
| 2012 Q3 | -3.08 Million ILS | -384.35% |
| 2012 Q4 | -4.81 Million ILS | -56.06% |
| 2012 Q2 | 1.08 Million ILS | 126.88% |
| 2011 FY | -22.04 Million ILS | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 61.065% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -343.834% |
| SQZ Biotechnologies Company | -79.46 Million USD | 63.27% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 155.092% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 144.811% |
| Mesoblast Limited | -87.95 Million USD | 66.816% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1503.216% |
| Genus plc | 7.9 Million USD | 469.456% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -167.974% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -686.662% |
| Marizyme, Inc. | -65.34 Million USD | 55.335% |
| ContraFect Corporation | -65.15 Million USD | 55.202% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -230.02% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -497.352% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1589.595% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -909.095% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -262.136% |
| MultiCell Technologies, Inc. | -380.07 USD | -7679274.852% |
| Accustem Sciences Inc. | -3.74 Million USD | -679.064% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 43.537% |
| EV Biologics, Inc. | -1.26 Million USD | -2203.387% |
| Q BioMed Inc. | -2.05 Million USD | -1322.304% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -681.864% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -4515.224% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1125.896% |
| Biomind Labs Inc. | -1.21 Million USD | -2303.569% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -176.706% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -269.311% |
| Skye Bioscience, Inc. | -37.64 Million USD | 22.467% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1245.138% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -194791.827% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -317.982% |
| IMV Inc. | -36.48 Million USD | 20.004% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -83.896% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -401.732% |
| GB Sciences, Inc. | -1.36 Million USD | -2043.46% |
| Alpha Cognition Inc. | -13.77 Million USD | -111.921% |
| HST Global, Inc. | -146.21 Thousand USD | -19862.383% |
| CSL Limited | 2.64 Billion USD | 101.105% |
| Halberd Corporation | -79.67 Thousand USD | -36532.11% |
| Enzolytics Inc. | -2.17 Million USD | -1240.802% |
| Resverlogix Corp. | -3.61 Million USD | -708.504% |
| Affymax, Inc. | -14.42 Million USD | -102.35% |
| SYBLEU INC | -180.3 Thousand USD | -16087.661% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -820.309% |
| argenx SE | -295.05 Million USD | 90.108% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 53.375% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 29882.653% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -634.635% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -864.498% |
| AVAX Technologies, Inc. | -6.41 Million USD | -355.076% |
| Zenith Capital Corp. | -10.59 Million USD | -175.453% |
| Genscript Biotech Corporation | -95.47 Million USD | 69.43% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -125478.694% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -603.991% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -48190.38% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 51.131% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -840.979% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -2663.771% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1397.346% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -664.258% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1355.627% |
| BioStem Technologies, Inc. | -8.48 Million USD | -244.065% |
| ONE Bio Corp. | 8.67 Million USD | 436.387% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -6512.834% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2085.587% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1563.294% |
| Agentix Corp. | -1.37 Million USD | -2023.91% |
| LadRx Corporation | 400.44 Thousand USD | 7388.678% |
| Cell Source, Inc. | -5.32 Million USD | -448.503% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -6924.904% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2951.663% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2951.663% |
| NovAccess Global Inc. | -4.76 Million USD | -511.991% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 521.498% |
| Itoco Inc. | -1.86 Million USD | -1461.641% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -556.99% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1648.772% |
| Kadimastem Ltd | -3.3 Million USD | -782.476% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -10575.489% |
| CytoDyn Inc. | -49.84 Million USD | 41.44% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -36830.143% |
| Mobile Lads Corp. | -2.26 Million USD | -1189.582% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -12694.189% |
| Qrons Inc. | -789.34 Thousand USD | -3597.613% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2999.958% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1298.058% |
| Rebus Holdings, Inc. | -1.02 Million USD | -2761.471% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1709.781% |
| International Stem Cell Corporation | -131 Thousand USD | -22180.153% |
| Bioxytran, Inc. | -4.28 Million USD | -581.939% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -53679.113% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1053.524% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 39.285% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1280.653% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -3637.673% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -821.307% |
| Neutra Corp. | -233.46 Thousand USD | -12401.66% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -43.842% |
| PureTech Health plc | -65.69 Million USD | 55.573% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -37.244% |
| IXICO plc | -1.17 Million USD | -2377.674% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -194.016% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 48.909% |
| CSL Limited | 2.64 Billion USD | 101.105% |
| Cellectis S.A. | -103.17 Million USD | 71.711% |